- Home
- CYCN vs BDRX Comparison
CYCN vs BDRX Comparison
Compare CYCN & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- BDRX
- Stock Information
- Founded
- CYCN 2018
- BDRX 2000
- Country
- CYCN United States
- BDRX United Kingdom
- Employees
- CYCN N/A
- BDRX N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- BDRX Health Care
- Exchange
- CYCN Nasdaq
- BDRX Nasdaq
- Market Cap
- CYCN 6.5M
- BDRX 5.8M
- IPO Year
- CYCN N/A
- BDRX N/A
- Fundamental
- Price
- CYCN $2.81
- BDRX $0.90
- Analyst Decision
- CYCN
- BDRX
- Analyst Count
- CYCN 0
- BDRX 0
- Target Price
- CYCN N/A
- BDRX N/A
- AVG Volume (30 Days)
- CYCN 21.8K
- BDRX 3.2M
- Earning Date
- CYCN 08-06-2025
- BDRX 04-11-2025
- Dividend Yield
- CYCN N/A
- BDRX N/A
- EPS Growth
- CYCN N/A
- BDRX N/A
- EPS
- CYCN N/A
- BDRX N/A
- Revenue
- CYCN $2,081,000.00
- BDRX N/A
- Revenue This Year
- CYCN N/A
- BDRX N/A
- Revenue Next Year
- CYCN N/A
- BDRX N/A
- P/E Ratio
- CYCN N/A
- BDRX N/A
- Revenue Growth
- CYCN N/A
- BDRX N/A
- 52 Week Low
- CYCN $1.27
- BDRX $0.78
- 52 Week High
- CYCN $9.47
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- CYCN 41.24
- BDRX 39.25
- Support Level
- CYCN $3.02
- BDRX $0.85
- Resistance Level
- CYCN $3.16
- BDRX $0.97
- Average True Range (ATR)
- CYCN 0.21
- BDRX 0.11
- MACD
- CYCN -0.03
- BDRX -0.00
- Stochastic Oscillator
- CYCN 16.26
- BDRX 28.24
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.